VivoSeq
Other

Seminoma

10

Pipeline Programs↗

6

Active Trials↗

3

Companies Involved↗

Seminoma is an early-stage landscape with 10 programs across 3 companies. The most active players are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Sanofi, Avyxa. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

80/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2A

Avyxa

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

12

clinical trials

Recruiting4 · 33%
Completed4 · 33%
Active, not recruiting2 · 17%
Unknown status1 · 8%
Terminated1 · 8%

Clinical Trials

Trial Activity

12 trials

De-escalation Study for Stage IIa/IIb < 3 cm Seminoma
Recruiting·CCentre Leon Berard·Phase 2·NCT05529251·90 enrolled
Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma
Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT01887340·271 enrolled
Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors
Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·N/A·NCT05705687·150 enrolled
PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND
Recruiting·HHeinrich-Heine University, Duesseldorf·Phase 2·NCT06144736·60 enrolled
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
Active, not recruiting·SSt. Olavs Hospital·Phase 3·NCT02341989·348 enrolled
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
Active, not recruiting·SSwiss Cancer Institute·Phase 2·NCT03937843·135 enrolled
Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours
Completed·IInstitute of Cancer Research, United Kingdom·Phase 3·NCT01726374·246 enrolled
A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors
Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT02115165·34 enrolled
Carboplatin AUC-10 With Early PET Scanning in Metastatic Seminoma
Completed·BBarts & The London NHS Trust·Phase 2·NCT02272816·48 enrolled
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
Completed·CCentre Leon Berard·Phase 2·NCT02104986·117 enrolled
Therapy De-escalation in Seminoma Stage IIA/B
Terminated·SSwiss Cancer Institute·Phase 2·NCT01593241·120 enrolled
Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors
Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT00127049·37 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)